MGMT and glioblastoma: The high‐risk subtype, associated with older age, poorer outcomes, astrocytoma/glioblastoma, higher tumor grades, elevated mesenchymal scores, and an inhibitory immune microenvironment, exhibited IDH wild‐type, 1p19q non‐codeletion, and MGMT promoter unmethylation, suggesting chemotherapy resistance.